35219-13-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(1,3,4-OXADIAZOL-2-YL)ANILINE is used as a reagent for the preparation of fused heterocyclic derivatives. These derivatives are of significant interest due to their potential as anticancer agents. 4-(1,3,4-OXADIAZOL-2-YL)ANILINE's unique structure allows for the development of new drugs that can target and combat cancer cells effectively.
Application Reason:
The use of 4-(1,3,4-OXADIAZOL-2-YL)ANILINE in the pharmaceutical industry is primarily driven by its ability to form fused heterocyclic derivatives with potential anticancer properties. These derivatives can be further modified and optimized to enhance their therapeutic effects, making them valuable candidates for the development of novel cancer treatments.

Upstream product

• 4291-13-8 2-(4-nitrophenyl)-1,3,4-oxadiazole 
• 1895-39-2 sodium chlorodifluoroacetate 
• 5351-17-7 4-aminobenzohydrazide 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 618-94-0 3-nitrobenzoic acid hydrazide 
• 636-97-5 N-amino-(4-nitrophenyl)carboxamide 
• 619-45-4 4-methoxycarbonyl aniline 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 150-13-0 4-amino-benzoic acid 
• 5565-72-0 2-(3-nitrobenzene)-1,3,4-oxadiazole 

Downstream Products

• 92906-14-4 4-nitro-N-(4-[1,3,4]oxadiazol-2-yl-phenyl)-benzenesulfonamide 
• 1071691-56-9 4-acetylamino-N-(4-[1,3,4]oxadiazol-2-yl-phenyl)-benzenesulfonamide 
• 6336-70-5 4-(4-aminobenzenesulfonylamino)benzoic acid 
• 1438423-94-9 (R)-2-(6-(4-(1,3,4-oxadiazol-2-yl)phenylamino)-5-cyanopyrazin-2-ylamino)butanamide 

Relevant academic research and scientific papers

[4u202f+u202f1] Cyclization of benzohydrazide and ClCF2COONa towards 1,3,4-oxadiazoles and 1,3,4-oxadiazoles-d5

A facile synthesis of 1,3,4-oxadiazoles and 1,3,4-oxadiazoles-d5 via [4 + 1] cyclization of ClCF2COONa with non-amine compounds containing amino groups is developed. Of note, this is the first time that halofluorinated compounds are used as C1 synthon to construct deuterated nitrogen-heterocyclic compounds. The current protocol features simple operation, readily accessible raw materials, wide substrate scope and valuable products

Discovery of a Potent Glutathione Peroxidase 4 Inhibitor as a Selective Ferroptosis Inducer

Potent and selective ferroptosis regulators promote an intensive understanding of the regulation and mechanisms underlying ferroptosis, which is highly associated with various diseases. In this study, through a stepwise structure optimization, a potent and selective ferroptosis inducer was developed targeting to inhibit glutathione peroxidase 4 (GPX4), and the structure-activity relationship (SAR) of these compounds was uncovered. Compound26aexhibited outstanding GPX4 inhibitory activity with a percent inhibition up to 71.7% at 1.0 μM compared to 45.9% of RSL-3. At the cellular level,26acould significantly induce lipid peroxide (LPO) increase and effectively induce ferroptosis with satisfactory selectivity (the value of 31.5). The morphological analysis confirmed the ferroptosis induced by26a. Furthermore,26asignificantly restrained tumor growth in a mouse 4T1 xenograft model without obvious toxicity.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.

17O NMR studies of substituted 1,3,4-oxadiazoles

Three series of substituted 1,3,4-oxadiazoles were studied by 17O NMR spectroscopy. Chemical shifts values were correlated with empirical Hammett parameters as well as calculated bond lengths and chemical shielding values.

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof

Characterization of 2-aryl-1,3,4-oxadiazoles by 15N and 13C NMR spectroscopy

15N NMR chemical shifts of 2-aryl-1,3,4-oxadiazoles were assigned on the basis of the 1H-15N HMBC experiment. Chemical shifts of the nitrogen and carbon atoms in the oxadiazole ring correlate with the Hammett σ-constants of substituents in the aryl ring (r2 ≥ 0.966 for N atoms). 15N NMR data are a suitable and sensitive means for characterizing long-range electronic substituent effects. Additionally, 13C NMR data for these compounds are presented. Copyright